Immunitrack provides a product and service pipeline to optimize immunogenicity assessments during drug development, as well as a broad portfolio of reagents to monitor patient CD8 and CD4 T cell responses to lead drug candidates during early R&D and clinical trials. The Major Histocompatibility Complex (MHC) is critical to the immune response. Immunitrack has world-leading expertise in the manufacture and application of MHC I and II molecules to accurately study MHC epitope binding through our proprietary NeoScreen® platform. Our aim is to help our customers predict the immune response. Immunogenicity prediction is a key need in the field of biologics, particularly for cancer vaccines. We want to help our customers to identify “real” epitopes (those that will cause a T-cell response) from pools of potential neo-epitopes generated by sequencing data. Our mission is to assist biotech and pharma companies in producing new biologics and vaccines faster, cheaper, more effectively and safer.
Total Funding: €71.4 K
Funding Stage: Funded
Business Stage: Scaling Up
Market: B2B
Company Size: 1 to 25
Founded: 2013
For AI Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI Startup founders or founders at Immunitrack
Immunitrack - AI Startup | AI Startup Profile Powered by Appengine AI | Appengine AI - AI Ecosystem of 12,000+ AI Startups
Immunitrack - Manage Profile
World's Most Promising AI Startups
World's Leading AI Ecosystem of AI Startups, Founders, Investors, and AI Professionals
Get Started